Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr;592(7855):616-622.
doi: 10.1038/s41586-021-03324-6. Epub 2021 Feb 10.

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Affiliations
  • PMID: 33567448
  • DOI: 10.1038/s41586-021-03324-6

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Zijun Wang et al. Nature. 2021 Apr.

Abstract

Here we report on the antibody and memory B cell responses of a cohort of 20 volunteers who received the Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccine against SARS-CoV-21-4. Eight weeks after the second injection of vaccine, volunteers showed high levels of IgM and IgG anti-SARS-CoV-2 spike protein (S) and receptor-binding-domain (RBD) binding titre. Moreover, the plasma neutralizing activity and relative numbers of RBD-specific memory B cells of vaccinated volunteers were equivalent to those of individuals who had recovered from natural infection5,6. However, activity against SARS-CoV-2 variants that encode E484K-, N501Y- or K417N/E484K/N501-mutant S was reduced by a small-but significant-margin. The monoclonal antibodies elicited by the vaccines potently neutralize SARS-CoV-2, and target a number of different RBD epitopes in common with monoclonal antibodies isolated from infected donors5-8. However, neutralization by 14 of the 17 most-potent monoclonal antibodies that we tested was reduced or abolished by the K417N, E484K or N501Y mutation. Notably, these mutations were selected when we cultured recombinant vesicular stomatitis virus expressing SARS-CoV-2 S in the presence of the monoclonal antibodies elicited by the vaccines. Together, these results suggest that the monoclonal antibodies in clinical use should be tested against newly arising variants, and that mRNA vaccines may need to be updated periodically to avoid a potential loss of clinical efficacy.

Update of

  • mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants.
    Wang Z, Schmidt F, Weisblum Y, Muecksch F, Barnes CO, Finkin S, Schaefer-Babajew D, Cipolla M, Gaebler C, Lieberman JA, Oliveira TY, Yang Z, Abernathy ME, Huey-Tubman KE, Hurley A, Turroja M, West KA, Gordon K, Millard KG, Ramos V, Da Silva J, Xu J, Colbert RA, Patel R, Dizon J, Unson-O'Brien C, Shimeliovich I, Gazumyan A, Caskey M, Bjorkman PJ, Casellas R, Hatziioannou T, Bieniasz PD, Nussenzweig MC. Wang Z, et al. bioRxiv. 2021 Jan 19:2021.01.15.426911. doi: 10.1101/2021.01.15.426911. Preprint. bioRxiv. 2021. PMID: 33501451 Free PMC article. Updated.

Comment in

Similar articles

  • mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants.
    Wang Z, Schmidt F, Weisblum Y, Muecksch F, Barnes CO, Finkin S, Schaefer-Babajew D, Cipolla M, Gaebler C, Lieberman JA, Oliveira TY, Yang Z, Abernathy ME, Huey-Tubman KE, Hurley A, Turroja M, West KA, Gordon K, Millard KG, Ramos V, Da Silva J, Xu J, Colbert RA, Patel R, Dizon J, Unson-O'Brien C, Shimeliovich I, Gazumyan A, Caskey M, Bjorkman PJ, Casellas R, Hatziioannou T, Bieniasz PD, Nussenzweig MC. Wang Z, et al. bioRxiv. 2021 Jan 19:2021.01.15.426911. doi: 10.1101/2021.01.15.426911. Preprint. bioRxiv. 2021. PMID: 33501451 Free PMC article. Updated.
  • Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies.
    Collier DA, De Marco A, Ferreira IATM, Meng B, Datir RP, Walls AC, Kemp SA, Bassi J, Pinto D, Silacci-Fregni C, Bianchi S, Tortorici MA, Bowen J, Culap K, Jaconi S, Cameroni E, Snell G, Pizzuto MS, Pellanda AF, Garzoni C, Riva A; CITIID-NIHR BioResource COVID-19 Collaboration, Elmer A, Kingston N, Graves B, McCoy LE, Smith KGC, Bradley JR, Temperton N, Ceron-Gutierrez L, Barcenas-Morales G; COVID-19 Genomics UK (COG-UK) Consortium, Harvey W, Virgin HW, Lanzavecchia A, Piccoli L, Doffinger R, Wills M, Veesler D, Corti D, Gupta RK. Collier DA, et al. Nature. 2021 May;593(7857):136-141. doi: 10.1038/s41586-021-03412-7. Epub 2021 Mar 11. Nature. 2021. PMID: 33706364
  • Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
    Weisblum Y, Schmidt F, Zhang F, DaSilva J, Poston D, Lorenzi JC, Muecksch F, Rutkowska M, Hoffmann HH, Michailidis E, Gaebler C, Agudelo M, Cho A, Wang Z, Gazumyan A, Cipolla M, Luchsinger L, Hillyer CD, Caskey M, Robbiani DF, Rice CM, Nussenzweig MC, Hatziioannou T, Bieniasz PD. Weisblum Y, et al. Elife. 2020 Oct 28;9:e61312. doi: 10.7554/eLife.61312. Elife. 2020. PMID: 33112236 Free PMC article.
  • Emerging Variants of SARS-CoV-2 And Novel Therapeutics Against Coronavirus (COVID-19).
    Aleem A, Akbar Samad AB, Slenker AK. Aleem A, et al. 2021 Jun 29. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–. 2021 Jun 29. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–. PMID: 34033342 Free Books & Documents. Review.
  • Will Mutations in the Spike Protein of SARS-CoV-2 Lead to the Failure of COVID-19 Vaccines?
    Jia Z, Gong W. Jia Z, et al. J Korean Med Sci. 2021 May 10;36(18):e124. doi: 10.3346/jkms.2021.36.e124. J Korean Med Sci. 2021. PMID: 33975397 Free PMC article. Review.

Cited by 211 articles

References

    1. Gaebler, C. & Nussenzweig, M. C. All eyes on a hurdle race for a SARS-CoV-2 vaccine. Nature 586, 501–502 (2020). - PubMed - DOI
    1. Jackson, L. A. et al. An mRNA vaccine against SARS-CoV-2 – preliminary report. N. Engl. J. Med. 383, 1920–1931 (2020). - PubMed - DOI
    1. Krammer, F. SARS-CoV-2 vaccines in development. Nature 586, 516–527 (2020). - PubMed - PMC - DOI
    1. Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603–2615 (2020). - PubMed - DOI
    1. Gaebler, C. et al. Evolution of antibody immunity to SARS-CoV-2. Nature, https://doi.org/10.1038/s41586-021-03207-w (2021).

Publication types

MeSH terms

Substances

Supplementary concepts

LinkOut - more resources

  • Full Text Sources

  • Other Literature Sources

  • Medical

  • Miscellaneous